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TECHNICAL NOTE

An analytical expression for R50% dependent on PTV surface
area and volume: A cranial SRS comparison
Dharmin D. Desai1 | E. L. Johnson2 | Ivan L. Cordrey1
1
Department of Radiation Oncology, CHI
Memorial Hospital, Chattanooga, TN, USA

Abstract

2

The intermediate dose spill for a stereotactic radiosurgery (SRS) plan can be quanti-

Department of Radiation Medicine,
University of Kentucky Chandler Medical
Center, Lexington, KY, USA

ﬁed with the metric R50%, deﬁned as the 50% isodose cloud volume (VIDC50%)
divided by the volume of the planning target volume (PTV). By coupling sound phys-
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ical principles with the basic deﬁnition of R50%, we derive an analytical expression
for R50% for a spherical PTV. Our analytical expression depends on three quantities:
the surface area of PTV (SAPTV), the volume of PTV (VPTV), and the distance of dose
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drop-off to 50% (Δr). The value of Δr was obtained from a simple set of cranial
phantom plan calculations. We generate values from our analytical expression for
R50% (R50%Analytic) and compare the values to clinical R50% values (R50%Clinical)
extracted from a previously published SRS data set that spans the VPTV range from
0.15 to 50.1 cm3. R50%Analytic is smaller than R50%Clinical in all cases by an average
of 15%  7%, and the general trend of R50%Clinical vs VPTV is reﬂected in the same
trend of R50%Analytic. This comparison suggests that R50%Analytic could represent a
theoretical lower limit for the clinical SRS data; further investigation is required to
conﬁrm this. R50%Analytic could provide useful guidance for what might be achievable in SRS planning.
KEY WORDS

cranial SRS/SRT, dose drop-off distance, PTV surface area, R50%Analytic, R50%

1 | INTRODUCTION

setting is likely a complex function of the size, shape, and location of
the PTV in the cranium, as well as delivery geometry, treatment

A cranial stereotactic radiosurgery (SRS) plan should be highly con-

modality, and optimization performance. Based on analyses of clinical

formal and have the steepest possible dose gradient outside of the

treatment plans, Goldbaum et al. and Ballangrud et al. have provided

planning target volume (PTV) to reduce complications associated

guidance on limiting values of the GI in cranial SRS planning utilizing

with excessive radiation delivered to normal brain tissues as mea-

the known PTV volume (VPTV).5,6 Knowledge of this limit may be

1

sured by the volume receiving 12 Gy or other intermediate dose

useful to the treatment planner as it provides a realistic goal to pur-

threshold. Several dose gradient metrics have been designed to

sue in the optimization.

quantify the intermediate dose spill outside the PTV. These include

Wang et al. noted that the original Radiation Therapy Oncology

gradient index (GI), gradient measure (GM), and R50%.2–4 The value

Group (RTOG) protocols 90-05 and 93-05 make no mention of inter-

of a given intermediate dose spill metric achievable in a clinical

mediate dose spill.7 However, the importance of intermediate dose
spill, as measured by GI or R50%, in SRS/SRT plan evaluation is now
widely recognized. Furthermore, two plans can have very similar high

*Joint ﬁrst authorship: Dharmin D. Desai and E. L. Johnson
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dose region conformity but have very different intermediate dose
spill. The plan with the larger intermediate dose spill does more damage to surrounding tissue; thus, a smaller GI or R50% would yield
less collateral damage. In this work, we examine the R50% metric to
better understand what limits can be expected for R50% in high
quality SRS/SRT plans.
Guidelines for intermediate dose spill metrics used in treatment
planning tend to be phenomenological constructs, and limits so
obtained are based on observations from large numbers of treatment
plans. We have proposed a model-based approach for the metric
R50% that considers the physical characteristics VPTV and PTV surface area (SAPTV). This approach allows for the derivation of an analytical form of R50% (R50%Analytic) that is based on physical
principles. It is necessary, however, that this analytical methodology
be validated against clinical data. At least one published study on
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R50% ¼

VIDC50% VPTV þ VIDC50%shell
VIDC50%shell
¼
¼1þ
VPTV
VPTV
VPTV

ET AL.

(1)

Furthermore, we determined an exact value of VIDC50%shell by
integrating the spherical differential shell volume, 4πr2dr, from r =rPTV to r = rPTV + Δr.
i
4 h
4πr2 dr ¼ π ðrPTV þ ΔrÞ3  r3PTV ¼
3
rPTV
"

 #
Δr 1 Δr 2
þ
4πr2PTV Δr 1 þ
rPTV 3 rPTV

VIDC50%shell ¼

rPTVRþΔr

(2)

Given that SAPTV ¼ 4πr2PTV and combining Eqs. (1) and (2), the
resulting analytical form of R50% can be expressed as:
R50%Analytic ¼ 1 þ

"



 #
SAPTV
Δr
1 Δr 2
Δr 1 þ
þ
rPTV
3 rPTV
VPTV

(3)

cranial SRS does provide the necessary data for a meaningful comparison of R50%Analytic to clinical data.8 Zhao et al. provided clear,

Equation (3) is a form of R50% for a spherical volume. We iden-

tabulated data for a wide range of PTV volumes from 0.15 to

tify the three components within the square brackets of Eq. (3) as

50.1 cm3. These clinical data sets are used to calculate R50% clinical

zeroth order, ﬁrst order, and second order terms, respectively. This

values (R50%Clinical), which are directly compared to our predicted

complete expression is an extension of previous work that only used

R50%Analytic values in this paper. Note: A list of abbreviations is pro-

the zeroth order term and, as expected, signiﬁcantly improves agree-

vided in the Appendix A.

ment for smaller PTV volumes.9,10

2 | MATERIALS AND METHODS

2.B | Δr determination

2.A | R50%Analytic derivation

One additional requirement of this analytical approach is an estimate
of the dose drop-off to 50% parameter, Δr, which cannot be calcu-

Consider a spherical PTV volume, VPTV, surrounded by a spherical

lated from ﬁrst principles at this time. However, it is possible to

shell that encloses the 50% isodose cloud volume (VIDC50%shell) as

obtain realistic estimates of Δr from treatment planning studies.

illustrated in Fig. 1. The sum of VPTV and VIDC50%shell is the total vol-

Note that Δr is likely different for different treatment modalities (i.e.,

ume encompassed by the 50% isodose cloud (VIDC50%). R50% is

Gamma Knife, Cyber Knife, and SRS capable Linacs) and should be

deﬁned as the ratio of the volume of the 50% Isodose Cloud to the

determined for each technology.

volume of the PTV as follows:

In our spherical model, the dose drop-off parameter Δr is the
value of linear distance from the edge of the PTV to the outer edge
of IDC50%shell as shown in Fig. 1 and is taken as isotropic.
To experimentally determine a value of Δr for the R50%Analytic
calculations, we utilized a treatment planning CT of the IROC SRS
Head Phantom (IROC Houston QA Center, Houston, TX) as the
anthropomorphic phantom model. Nine spherical PTVs were created in the center of the cranium with volumes ranging from 0.19
to 44 cm3. Treatment planning was performed on an Eclipse radiation treatment planning system (RTPS) using the photon optimizer
PO v15.6 with a ﬁnal calculation via the AAA v 15.6 algorithm on
a 1 mm calculation grid size. All plans were created for a Varian
TrueBeam STx with a 120 leaf HD MLC and used volumetric modulated arc therapy (VMAT, RapidArc) techniques. The delivery
geometry employed in this study to determine Δr used ﬁve hemiarcs spanning 150° arc angles at ﬁve couch angles as shown in
Fig. 2. This geometry is both clinically reasonable and highly con-

F I G . 1 . Plane through the center of the spherical volumes. Inner
volume is the planning target volume (PTV). The shaded region is
the spherical shell bounded by the 50% isodose cloud and the PTV
surface area. Δr is the radial thickness of the shell, as well as the
distance of dose drop-off from the edge of the PTV to 50%.

formal for a central cranial tumor because it uses nearly a full 2π
solid angle. The prescription for PTVs with a volume ≤ 3 cm3 was
18 Gy in one fraction with 99% of the VPTV receiving the dose;
the prescription for PTVs with a volume > 3 cm3 was 27 Gy in
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shell, middle control shell, and outer control shell) as described by
Clark et al. to directly limit the dose spill outside the PTV, in accordance with standard clinical practices.12 Alternatively, one could
use other dose limiting shell techniques.13 We sought the minimum
value of Δr one could obtain clinically in ideal circumstances. The
quality of these phantom plans can be seen from the parameters
given in Table 1.
Since a highly noncoplanar delivery geometry coupled with a
spherical PTV was chosen, the resulting dose distribution is reasonably
isotropic and can be assumed spherical. This nearly spherical dose distribution can be clearly seen in Fig. 3 as the transparent yellow isodose cloud of 50% of the prescription dose (IDC50%) surrounding the
solid orange PTV. This distribution bears a marked similarity to Fig. 1
used in the derivation of R50%Analytic. Thus, it becomes simple to
extract a value of Δr for each phantom PTV as follows:
Δr ¼ rIDC50%  rPTV
F I G . 2 . The ﬁve hemi-arcs beam arrangement for determination of
Δr. This three-dimensional (3D) view of the IROC head phantom
shows the beam delivery geometry used for the phantom plans used
to determine Δr for a series of nine spherical planning target
volumes. Each red curve in the ﬁgure represents the path of an arc
around the cranium using the Varian IEC scale. For couch angles
355° (A), 315° (B), and 270° (C), the arcs span 195° to 345°. For
couch angles 45° (D) and 5° (E), the arcs span 15° to 165°.

(4)

Based on the values of Δr obtained from the phantom study, a
power law ﬁt was generated (Microsoft Excel) for Δr as a function
of VPTV as shown in Fig. 4.
The resulting power law expression for Δr, in units of cm, is:
0:1973
Δr ¼ 0:2844  VPTV

(5)

where VPTV is measured in cm3.
As can be seen in Table 1, the GM values reported by Eclipse for
these spherical volumes are nearly identical to the Δr values

three fractions with 99% of VPTV receiving the prescription dose

obtained from Eq. (4). This should not be surprising since GM is

(D99% volumetric prescription). One could also use a percent iso-

deﬁned as the difference, in centimeters, of the equivalent sphere

dose line (PIDL) prescription to achieve the same volumetric PTV

radii of VIDC50% and VIDC100% (r50%eq and r100%eq, respectively).7

coverage as one achieves with the volumetric prescription.11 Ulti-

Thus,

mately, we just need 99% of the PTV volume covered by the pre-

GM ¼ r50%eq  r100%eq

scription dose consistently for all plans that determine Δr such that

(6)

CI is very nearly 1.0. Eclipse NTO (Normal Tissue Objective) was

By comparison, for a perfectly conformal plan (CI = 1.0),

used in conjunction with three dose control shells (inner control

VIDC100% is identical to and spatially coincident with VPTV. Thus, for

T A B L E 1 Summary of treatment planning properties obtained from the IROC SRS head phantom study to determine the value of Δr.
VPTV (cm3)

rPTV (cm)

CIRTOG

HIRTOG

GM (cm)

rIDC50% (cm)

Δr (cm)

PIDL

0.19

0.36

1.18

1.80

0.20

0.57

0.22

57.3

0.55

0.51

0.99

1.26

0.25

0.76

0.25

80.8

0.99

0.62

1.04

1.38

0.27

0.90

0.28

72.8

1.96

0.78

1.04

1.36

0.30

1.09

0.31

83.2

2.96

0.89

1.03

1.31

0.34

1.23

0.34

78.5

3.97

0.98

1.04

1.27

0.35

1.34

0.36

79.6

6.93

1.18

0.99

1.22

0.40

1.58

0.40

85.4

20.45

1.70

0.99

1.21

0.52

2.22

0.52

88.7

43.99

2.19

0.99

1.21

0.65

2.83

0.64

91.7

Ave CIRTOG

1.03

Std Dev

0.06

CIRTOG is the conformity index, and HIRTOG is the homogeneity index. All plans are normalized volumetrically to D99% (99% of the PTV volume receives
100% of the prescription dose). The equivalent PIDL is determined by matching the coverage of the D99% prescription. Δr values are calculated from
the difference of rIDC50% and rPTV, assuming both volumes are spherical. Note the Eclipse GM values are nearly identical to Δr.
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F I G . 3 . Typical results for the phantom study to determine Δr. The diagram shows an AP DRR and a right lateral DRR that display the
position and size of the PTV (solid orange shape) and IDC50% (transparent yellow shape) within the cranium. The distance from the edge of
the PTV and the outer edge of IDC50% is Δr. The volume of the PTV is 3 cm3. Note that the IDC50% is very nearly spherical.

GI ¼

VIDC50%
VIDC100%

(7)

and
CIRTOG ¼

VIDC100%
VPTV

(8)

R50% can be seen as the product of Eqs. (7) and (8).
R50% ¼

VIDC50% VIDC50% VIDC100%
¼

¼ GI  CIRTOG
VPTV
VIDC100%
VPTV

(9)

Using this approach, the data of Zhao et al. will yield the equivalent R50% to be used for comparison.

3 | RESULTS
Table 2 contains VPTV, CIRTOG, and GI values directly transcribed
F I G . 4 . Phantom study derived Δr as a function of VPTV. A good
ﬁt is obtained with the power law function shown.

from Zhao et al., values calculated from the clinical data, and the
subsequently generated R50%Analytic values. The parameter rPTV was
calculated using an assumption that PTV is spherical, and thus, it is
an equivalent sphere radius of the PTV. SAPTV is the surface area of

a spherical PTV, r100%eq = rPTV. Furthermore, if IDC50% is assumed

the equivalent sphere PTV. R50%Clinical was obtained by multiplying

to be spherical, r50%eq = rIDC50%. Therefore, it is reasonable to

the clinical CIRTOG and GI values provided by Zhao et al. [Eq. (9)].

assume that for nearly spherical volumes, the GM values obtained

Table 2 also displays the %Difference between the values of

from Eclipse can be considered equivalent to Δr. For simplicity, Δr

R50%Clinical and R50%Analytic. R50%Analytic values are uniformly smal-

was only considered as a function of VPTV.

ler than R50%Clinical values by an average of 15%  7%. A quick
observation conﬁrms that for smaller PTV volumes the R50%Clinical

2.C | Comparison methodology

values are signiﬁcantly larger than the R50%Analytic results obtained
from Eq. (3). As an example, for the smallest PTV volume (0.15 cm3),

To validate the clinical relevancy of R50%Analytic, we compared val-

R50%Clinical is 34.3% larger than R50%Analytic. These data are also

ues generated from Eq. (3) to R50%Clinical values obtained from a

shown graphically in Fig. 5, which indicates the larger R50%Clinical

published data set. Zhao et al. performed a retrospective analysis

values over the PTV volume range included in this study.

of 30 clinical cases and investigated an optimal prescription isodose
line that yields the steepest dose fall-off (smallest GI) outside the
PTV for cranial SRS plans. While R50% values are not directly

4 | DISCUSSION

presented in the retrospective analysis, clinical values for GI and
CIRTOG values are given for all 30 cases. Given the following deﬁni-

It can be readily seen that R50%Analytic values are consistently lower

tions of GI and CIRTOG,

than the corresponding R50%Clinical data (Fig. 5). Consideration of
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T A B L E 2 Clinical data and comparison of R50%Analytic values to R50%Clinical values.
CIRTOG(a)

GI(a)

R50%Clinical(b)

Δr (cm)

R50%Analytic

%Diff of R50% Values

1.37

1.59

3.87

6.15

0.20

4.05

−34.26

0.37

1.71

1.30

3.50

4.55

0.21

3.85

−15.47

0.45

2.49

1.61

3.14

5.06

0.23

3.54

−29.88

0.44

0.47

2.80

1.27

3.07

3.90

0.24

3.46

−11.25

0.48

0.49

2.96

1.30

3.19

4.15

0.25

3.42

−17.55

0.53

0.50

3.17

1.32

3.06

4.04

0.25

3.37

−16.49

0.61

0.53

3.48

1.23

3.00

3.69

0.26

3.31

−10.31

0.75

0.56

3.99

1.24

2.90

3.60

0.27

3.22

−10.46

1.30

0.68

5.76

1.21

2.75

3.33

0.30

3.00

−9.83

1.80

0.75

7.15

1.33

2.76

3.67

0.32

2.88

−21.48

2.10

0.79

7.93

1.25

2.62

3.28

0.33

2.83

−13.61

2.60

0.85

9.14

1.28

2.70

3.46

0.34

2.76

−20.18

3.10

0.90

10.28

1.14

2.57

2.93

0.36

2.70

−7.74

4.20

1.00

12.59

1.08

2.51

2.71

0.38

2.61

−3.67

4.70

1.04

13.57

1.20

2.48

2.98

0.39

2.58

−13.34

4.80

1.05

13.76

1.22

2.55

3.11

0.39

2.57

−17.29

6.10

1.13

16.14

1.15

2.41

2.77

0.41

2.51

−9.56

6.90

1.18

17.52

1.15

2.47

2.84

0.42

2.47

−12.91

7.30

1.20

18.20

1.16

2.48

2.88

0.42

2.46

−14.52

7.80

1.23

19.02

1.16

2.45

2.84

0.43

2.44

−14.08

9.50

1.31

21.69

1.22

2.68

3.27

0.44

2.39

−26.83

11.40

1.40

24.49

1.05

2.39

2.51

0.46

2.35

−6.42

12.60

1.44

26.18

1.11

2.44

2.71

0.47

2.32

−14.16

14.10

1.50

28.22

1.06

2.39

2.53

0.48

2.30

−9.25

18.80

1.65

34.19

1.12

2.36

2.64

0.51

2.24

−15.43

21.30

1.72

37.15

1.14

2.42

2.76

0.52

2.21

−19.93

27.30

1.87

43.84

1.27

2.13

2.71

0.55

2.16

−20.21

34.40

2.02

51.14

1.07

2.31

2.47

0.57

2.11

−14.50

41.70

2.15

58.14

1.06

2.29

2.43

0.59

2.08

−14.42

50.10

2.29

65.71

1.07

2.24

2.40

0.62

2.04

−14.71

Ave %Diff

−15.32

VPTV(a) (cm3)

rPTV(c) (cm)

0.15

0.33

0.21
0.37

SAPTV(b) (cm2)

Std Dev

6.63

Values shown are actual and calculated parameters from Zhao et. al. SAPTV values were calculated assuming spherical PTVs in the Zhao et al. data. Also
shown are values of Δr and R50%Analytic obtained from Eqs. (4) and (3), respectively. (a)values given by Zhao et al. (b)values calculated from Zhao et al.
(c)
value calculated from Zhao et al. based on spherical PTV assumption.

the treatment planning conditions of Zhao et al. may provide a basis

delivery geometry for a Linac-based SRS delivery. Clinical PTVs,

for a reasonable explanation of the differences observed. The clinical

however, are not ideal spheres, and dose drop-offs are not perfectly

data presented by Zhao et al. are a composite of situations inﬂu-

isotropic around the PTV. Also, clinical considerations of organs at

enced by a wide range of conditions: unique prescription doses,

risk in proximity of the PTV were not included in the R50%Analytic

diverse sizes and shapes, various locations in the brain, and variable

model. As a result, the R50%Analytic model, as indicated by Eq. (3),

proximity to different organs at risk among other restrictions. The

should be considered as a theoretical lower limit of R50% for

distance of dose drop-off from PTV surface to 50% (Δr) is likely

intracranial targets.

affected by some of these conditions. In contrast, consider the ideal

We measured Δr in a simple planning study of spherical targets

conditions assumed in the derivation of Eq. (3). For simplicity, isotro-

of varying volumes. Our planning study used VMAT (RapidArc) deliv-

pic dose drop-offs from PTV surface to 50% were assumed around

ery. A similar study could be done to determine Δr using dynamic

spherical PTVs, which implies a 4π delivery geometry. In most realis-

conformal arc therapy (DCAT), and the values of Δr so obtained

tic scenarios, the treatment of cranial targets can achieve a 2π

could be different. The data provided by Zhao et al. for the replan
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we measure Δr for the case of spherical targets. Yet, the value of Δr
is not the primary focus of this work. Our primary focus is testing
the equation R50%Analytic against the clinical data provided by Zhao
et al.
Goldbaum et al. noted that a group of plans with very similar
PTV volumes produced a wide range of R50% values. They hypothesized that the increase in R50% could be related to variations in
SAPTV but were not able to quantify the relationship. Although this
current study only considered spherical volumes, the dependence on
SAPTV is explicit in Eq. (3), and conceptually, this analytic model
should be able to account for variations in SAPTV. In fact, the model
would predict larger R50% values for targets with increased SAPTV
to VPTV ratios, which is consistent with the suppositions in Goldbaum et al. In previous work, it was quantitatively shown that an
increase in the SAPTV to VPTV ratio leads to an increase in R50% values.9 For any given volume, the shape that corresponds to the smallF I G . 5 . Comparison of R50%Clinical and R50%Analytic as functions of
the VPTV in the range from 0.15 to 50.1 cm3. This is a graphical
representation of the data in Table 2. The R50%Clinical values are
extracted from the clinical study of Zhao et al. The values of
R50%Analytic are calculated from Eq. (3). Note that the general trend
of R50%Clinical as a function of VPTV is reﬂected in the same trend of
R50%Analytic. Furthermore, the R50%Clinical values are consistently
larger than the R50%Analytic values.

est surface area is a sphere,16 and the assumption of a spherical PTV
with an isotropic dose drop-off is central to the construction of our
analytic equation for R50% [Eq. (3)]. This reﬂects an ideal case, and
therefore, it would be reasonable to argue that the analytical equation yields the smallest possible R50% (the R50% lower limit). Zhao
et al. provided VPTV values for their study but did not provide SAPTV
data. However, this is not unexpected since commercial treatment
planning systems do not include surface area as part of the structure
statistics as they report (like VPTV). Without available surface area

of clinical cases were done using DCAT delivery. If the Δr was larger

information, we assumed a spherical PTV (smallest surface area) and

as a function of VPTV using DCAT delivery, the agreement with the

calculated SAPTV from the provided VPTV values; the calculated

data provided by Zhao et al. would improve. However, our goal in

SAPTV values were then used in Eq. (3) to generate R50%Analytic. The

this work was to provide the minimum achievable R50% as

actual clinical PTV shapes in the data of Zhao et al. are likely to have

described by R50%Analytic. We chose to determine Δr using VMAT

some nonspherical character.

techniques because VMAT delivery of SRS/SRT is rapidly gaining
popularity, particularly for multiple target cases.6,11

At lower VPTV values, a larger difference is seen between
R50%Clinical and R50%Analytic (Fig. 5), which indicates that caution

There are other ways to measure or estimate Δr and similar

should be taken when evaluating clinical values of R50% at low PTV

quantities. We used a simple planning study and the GM functional-

volumes. Zhao et al. suggested that, for small PTV volumes, dose

ity built into Eclipse. Sung and Choi use proprietary software to

drop-off is extremely sensitive to location, target shape, and beam

determine cumulative dose gradient index (cDGI), a metric of their

settings and discussed the limitation of treatment planning systems

creation similar to Δr in the case of the cDGI for the 50% of pre-

to accurately compute dose for small targets. Our analytic form does

scription dose (cDGI50%).14 They determine the cDGI50% for a

not suffer from those clinical and technical challenges, and thus, it is

3 cm diameter spherical target (VPTV = 14.14 cm3) to be cDGI50% =

a reasonable assumption that, for a certain VPTV, the smallest theo-

5.98 mm. Our empirical formula for Δr [Eq. (5)] for that same vol-

retical R50% value is expressed by Eq. (3). This prediction could be

ume yields Δr = 4.80 mm, which is comparable to the value of

used as a guide for the treatment planner to consider, among other

cDGI50%. R50%Analytic will be a larger value if one uses cDGI50% as

factors, when progressing through the plan optimization. A set of

the estimate for Δr. Zhang et al. propose yet another novel metric

PTVs of a given volume could have different shapes and, thus, dif-

they call dose-dropping speed (DDS).15 Dose-dropping speed cer-

ferent surface areas. Equation (3) clearly shows that a larger surface

tainly has relationship to Δr and shows similar dependence on VPTV,

area PTV should have a larger R50%. As such, knowing the SAPTV

which they describe in terms of PTV diameter. In fact, to compare

and recognizing that a larger surface area guarantees a higher R50%

values for 1/DDS to our Δr values, one ﬁnds they are within 0.1 mm

value can be useful at the onset of the treatment planning process.

for a 0.9 cm3 target and within 1.4 mm for a 61.6 cm3 target, with

Based on the comparison results with Zhao et al., a plan with R50%

the Zhang et al. determined values of 1/DDS being the larger values.

within 15% of the R50%Analytic would be a plan with excellent inter-

In our work, we do not propose a new metric but rather a way

mediate dose spill.

to predict the minimum value of an established metric, R50%, for an

It is possible that R50%Analytic could be used for automated plan-

SRS/SRT case based on three parameters: VPTV, SAPTV, and Δr.

ning or artiﬁcial intelligence planning systems that seek to control

Because Δr cannot be calculated from ﬁrst principles at this time,

intermediate dose spill.13 As such, R50%Analytic would be used as the
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target or goal R50% of the automated planning. R50%Analytic, as
expressed in Eq. (3), may not be achievable in all circumstances, but
as stated above, a plan within 15% of the R50%Analytic is a plan
with excellent intermediate dose spill.
Understanding intermediate dose spill when multiple PTVs are
optimized simultaneously using a single isocenter is not a trivial task.
It depends on several factors: relative locations and sizes of PTVs
with respect to one another (e.g., a large PTV in close proximity to a
much smaller PTV), plan delivery geometry, plan optimization performance, etc. There is no easy or straight forward way to account for
an increase in R50% of a PTV due to its location with respect to
another PTV. Drawing from comments of Bohoudi et al. and Goldbaum et al. stating that their results obtained for intermediate dose
spill around single cranial targets should apply to multiple cranial target cases as well,5,17 we expect R50%Analytic to perform well in predicting the theoretical minimum R50% for individual PTVs in multiple
target cranial SRS/SRT cases. This will need to be conﬁrmed by further investigation.

5 | CONCLUSION
An analytical expression for R50% was derived for the special case
of spherical volumes. The expression appears to provide a lower limit
of R50% when compared to peer-reviewed, clinical data. We surmise
that SAPTV plays an important role in the determination of the R50%
value ultimately achievable in treatment planning. Further research is
needed to establish the role of SAPTV for other PTV shapes in the
determination of treatment planning outcomes. Research is also
needed to establish methods for obtaining Δr and investigate additional determining factors beyond VPTV.
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6. Ballangrud Å, Kuo LC, Happersett L, et al. Institutional experience
with SRS VMAT planning for multiple cranial metastases. J Appl Clin
Med Phys. 2018;19:176–183.
7. Wang D, DeNittis A, Hu Y. Strategies to optimize stereotactic radiosurgery plans for brain tumors with volumetric-modulated arc therapy. J Appl Clin Med Phys. 2020;21:45–51.
8. Zhao B, Jin JY, Wen N, et al. Prescription to 50–75% isodose line
may be optimum for linear accelerator based radiosurgery of cranial
lesions. J Radiosurg SRBT. 2014;3:139–147.
9. Desai DD, Cordrey IL, Johnson EL. A physically meaningful relationship between R50% and PTV surface area in lung SBRT. J Appl Clin
Med Phys. 2020;21:47–56.
10. Desai DD, Johnson EL, Cordrey IL. An analytical expression for
R50% dependent on PTV surface area and volume: a lung SBRT
comparison. J Appl Clin Med Phys. 2020;21:278–282.
11. Xu Y, Ma P, Xu Y, Dai J. Selection of prescription isodose line for
brain metastases treated with volumetric modulated arc radiotherapy. J Appl Clin Med Phys. 2019;20:63–69.
12. Clark GM, Popple RA, Prendergast BM, et al. Plan quality and treatment planning technique for single isocenter cranial radiosurgery
with volumetric modulated arc therapy. Pract Radiat Oncol.
2012;2:306–313.
13. Rossi L, Romero AM, Milder M, de Klerk E, Breedveld S, Heijmen B.
Individualized automated planning for dose bath reduction in robotic
radiosurgery for benign tumors. PLoS One. 2019;14:e0210279.
14. Sung K, Choi YE. Dose gradient curve: a new tool for evaluating
dose gradient. PLoS One. 2018;13:e0196664.
15. Zhang Q, Zheng D, Lei Y, et al. A new variable for SRS plan quality
evaluation based on normal tissue sparing: the effect of prescription
isodose levels. Br J Radiol. 2014;87:20140362.
16. Kleiner B. An isoperimetric comparison theorem. Invent Math.
1992;108:37–47.
17. Bouhoudi O, Bruynzeel AME, Lagerwaard FJ, Cuijpers JP, Slotman
BJ, Palacios MA. Isotoxic radiosurgery planning for brain metastases.
Radiother Oncol. 2016;120:253–257.

210

|

DESAI

ET AL.

APPENDIX A
ABBREVIATIONS
Table A1 contains deﬁnitions for abbreviations used throughout this
article.
T A B L E A 1 List of abbreviations with deﬁnitions.
Abbreviation

Deﬁnition

cDGI

Cumulative dose gradient index

CIRTOG

RTOG conformity index

D99%

99% of PTV volume covered by 100% of prescription dose

DDS

Dose-dropping speed

GI

Gradient index

GM

Gradient measure

HIRTOG

RTOG homogeneity index

IDC

Isodose cloud

IDC50%

50% (of prescription dose) isodose cloud

IDC50%shell

Distance from the edge of the planning target volume to the edge of the 50% isodose cloud

IDC100%

100% (of prescription dose) isodose cloud

NTO

Normal tissue objective; Instructs the optimizer to limit dose to non-target volumes

OAR

Organs at risk

PIDL

Prescription isodose line

PTV

Planning target volume

Δr

Distance of dose drop-off from the edge of the planning target volume to 50% dose

rIDC50%

Radius of the 50% isodose cloud

rPTV

Radius of the planning target volume

r50%eq

Equivalent sphere radius of the volume of the 50% isodose cloud

r100%eq

Equivalent sphere radius of the volume of the 100% isodose cloud

R50%

Ratio of the volume of the 50% isodose cloud to the volume of the planning target volume

R50%Analytic

Value of R50% generated from our analytical expression

R50%Clinical

Value of R50% calculated from clinical data

RTPS

Radiation treatment planning system

SAPTV

Surface area of the planning target volume

SRS

Stereotactic radiosurgery

SRT

Stereotactic radiotherapy

VIDC50%

Volume of the 50% isodose cloud

VIDC50%shell

Volume of the 50% isodose cloud minus the volume of the planning target volume

VIDC100%

Volume of the 100% isodose cloud

VPTV

Volume of the planning target volume

VMAT

Volumetric modulated arc therapy

